Compare DexCom, Inc. (DXCM) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Wendys Co — how do they compare? DexCom, Inc. trades at $77.54 (market cap $28.06B), while Wendys Co trades at $7.71 (market cap $1.42B). The key difference: DexCom, Inc. is far larger — about 19.8× Wendys Co's market cap, and Wendys Co pays a 7.53% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | WEN | |
|---|---|---|
Market Cap | $28.06B | $1.42B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $11.33 |
52-Week Low | $54.84 | $6.17 |
Enterprise Value | $27.03B | $5.23B |
Dividend Yield | — | 7.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Wendy's (WEN) trades at $7.60, up 2.43% today, with technicals showing a bearish trend but oversold RSI signals. The stock has beaten earnings estimates for three consecutive quarters, though net income margins have declined from 9.37% in 2023 to 6.77% in 2025. Recent news highlights Project Fresh initiatives and meme-driven volatility, with a dividend yield of 7.1% based on the latest payout.
The outlook is mixed: low P/E of 9.66 and high ROE of 120.88% suggest value, but declining profitability and bearish analyst consensus (62.75% hold) signal caution. Key risks include U.S. traffic pressures and cost inflation, while potential catalysts are digital growth and China expansion. Investors face a trade-off between deep value and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
